VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Yao on Takeaways From the RADIANT-3 Trial

James C. Yao, MD
Published: Friday, Oct 10, 2014

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses key takeaways from the RADIANT-3 trial for a community oncologist.

RADIANT-3 showed significant improvement in progression-free and overall survival, including in patients with progressive disease.

After longer follow-up, the safety profile of everolimus looked consistent with what was seen before. Yao notes that a particular interesting fact about everolimus in this space is that an adverse event, stomatitis, was associated with better outcomes for patients. This finding was presented as part of a meta-analysis at the 2014 ASCO meeting.

<<< View more from NANETS

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses key takeaways from the RADIANT-3 trial for a community oncologist.

RADIANT-3 showed significant improvement in progression-free and overall survival, including in patients with progressive disease.

After longer follow-up, the safety profile of everolimus looked consistent with what was seen before. Yao notes that a particular interesting fact about everolimus in this space is that an adverse event, stomatitis, was associated with better outcomes for patients. This finding was presented as part of a meta-analysis at the 2014 ASCO meeting.

<<< View more from NANETS


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x